Just to clarify the above:

"Tam01 is a phase three trial of low-dose Tamoxifen in women with high-risk lesions, including DCIS, atypical ductal hyperplasia and lobular carcinoma in situ."

Note the word "lesions." Some of these are now termed "pre-cancers."

So this study does not relate to invasive cancers that , it seems. Am I missing something?

Also most of us are told that after menopause, we should be on aromatase inhibitors, which are more effective for us than tamoxifen. Or that is what I was told.

I would like to see a study that proves baby Tam works for invasive cancers at this low dose and is still effective for these more severe cancers.